Although ischemic event rates were lower in the ticagrelor/prasugrel group than in the clopidogrel group (RR = 0.75 and 0.76, p = 0.770), the difference did not reach statistical significance. 5. Discussion Cangrelor, which is the only intravenous P2Y12 inhibitor, is critical for ACS management [ 23 , 24 ].
1
—
—